Nalu Bio, Inc.
AI-driven drug discovery platform targeting endocannabinoid system (ECS) therapeutics for chronic inflammation and metabolic dysfunction
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2019
- Latest Form D
- $4.8M, Mar 2023
- Total capital
- $4.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4.8M
- 1 Form D · last Mar 2023
- 44 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 10 pending · first 2025
- Rank in peer group#43 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#43 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Caitlyn KrebsExecutive Officer, DirectorNamed in SEC Form D filings
- Howard E. GoodwinDirectorNamed in SEC Form D filings
- Phyllis E. WhiteleyExecutive Officer, DirectorNamed in SEC Form D filings
- Randall S. UsseryDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 14- GrantedAryl-substituted N-alkyl Indoles And Their Use As Pharmacologically Active AgentsUSPTOUS 12,679,847
- GrantedCannabinol Analogs And Their Use As Pharmacologically Active AgentsUSPTOUS 12,636,296
- GrantedCannabinoid Analogs, Formulations, And Methods Of UseUSPTOUS 12,583,832
Show all 14 patent records
- Aryl-substituted N-alkyl Indoles And Their Use As Pharmacologically Active AgentsJul 14, 2026 · US 12,679,847Granted
- Cannabinol Analogs And Their Use As Pharmacologically Active AgentsMay 26, 2026 · US 12,636,296Granted
- Cannabinoid Analogs, Formulations, And Methods Of UseMar 24, 2026 · US 12,583,832Granted
- Synthesis Of (-)-TRANS-DELTA-9-TETRAHYDROCANNABIVARIN (DELTA-9 Thcv) And Analogs ThereofOct 30, 2025 · Application 19173695Pending
- Synthesis Of Cannabinoids And Cannabinoid Precursors, And Related Compounds, Formulations, And Methods Of UseAug 28, 2025 · Application 19208427Pending
- Synthesis Of Cannabinoids And Cannabinoid Precursors, And Related Compounds, Formulations, And Methods Of UseApr 1, 2025 · US 12,264,143Granted
- Synthesis Of Cannabidiol And Analogs Thereof, And Related Compounds, Formulations, And Methods Of UseSep 26, 2024 · Application 18268181Pending
- Synthesis Of Cannabidiol And Analogs Thereof, And Related Compounds, Formulations, And Methods Of UseNov 9, 2023 · Application 18212061Pending
- Synthesis Of Cannabidiol And Analogs Thereof, And Related Compounds, Formulations, And Methods Of UseApplication PCTUS2021064243Pending
- Synthesis Of (-)-trans- 9-TETRAHYDROCANNABIVARIN ( 9-THCV) And Analogs ThereofApplication PCTUS2025023726Pending
- Synthesis Of (-)-TRANS-DELTA-9-TETRAHYDROCANNABIVARIN And Analogs ThereofApplication PCTUS2024034735Pending
- Synthesis Of (-)-TRANS-DELTA-9-TETRAHYDROCANNABIVARIN (DELTA-9 Thcv) And Analogs ThereofApplication 63640638Pending
- Synthesis Of (-)-TRANS-DELTA-9-TETRAHYDROCANNABIVARIN (DELTA-9 Thcv) And Analogs ThereofApplication 63631401Pending
- Synthesis Of (-)-TRANS-DELTA-9-TETRAHYDROCANNABIVARIN And Analogs ThereofApplication 63510058Pending
Related companies, and why
- Persist AI Formulations CorpSimilar federal contract value in Biotech · null in contracts
- Hapten Sciences Development, LLCSimilar federal contract value in Biotech · null in contracts
- Digit Technologies Inc.Similar federal contract value in Biotech · null in contracts
- Latent Labs Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- Seek Laboratories, Inc.Similar federal contract value in Biotech · null in contracts
- Kanvas Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .